RNAseq data from 60 tumor samples obtained prior to chemotherapy and also showed improved overall survival in patients with high PDCD1 and CD8A expression, median OS 20.5 vs 9.3 months (HR 0.475, p = 0.017, Fig. 3b). Here, CD8A is linked to neoplasm.